Leadership
Pharma’s new CEOs to watch
Novo Nordisk, Sanofi, and GSK have each welcomed new CEOs over the past year. The three leaders assumed their roles at pivotal moments for their respective companies, facing challenges such as competition in the obesity drug market, expiration of core product patents, and pipeline restructuring. This article reviews the core tasks and latest developments for the three CEOs since taking office.
Trump nominates policy aide Overton to lead FDA
President Donald Trump on Wednesday nominated Heidi Overton, a top White House policy aide and physician, to lead the Food and Drug Administration. The announcement was made by Health and Human Services Secretary Robert F. Kennedy Jr. via a post on X, following a Bloomberg News report on Tuesday evening. Overton, who lacks drug regulatory experience, would step into an agency that has faced leadership turmoil and policy unpredictability. If confirmed by the Senate, she would replace interim commissioner Kyle Diamantas, who has been seen as a stabilizing force. Industry analysts express uncertainty about her impact on biopharma and drug review flexibility.
BioNTech’s oncology pivot comes with a new CEO
BioNTech, once a household name due to its COVID-19 vaccine, is returning to its oncology roots. With Comirnaty sales plummeting and a net loss of $1.56 billion in the first half of 2026, the company has appointed Guido Oelkers as its new CEO, effective by Feb. 1, 2027. Oelkers, who quadrupled Sobi's revenue since 2017, will oversee the transition of BioNTech's cancer pipeline into a sustainable business, leveraging a cash position of $19.2 billion. The company faces challenges including political attacks on mRNA technology, planned layoffs of up to 1,860 jobs, and the departure of co-founders Ugur Sahin and Özlem Türeci by end of 2026.
Specialty pharma has an infrastructure problem, and IT can’t solve it alone
Courier Health's annual survey shows that 83% of biopharma companies now manage field access and reimbursement internally, with internal ownership of patient services rising from 48% to 54%. However, nearly 60% of commercial leaders cannot reliably access and analyze data, and fewer than 10% have achieved the data maturity needed to support AI use cases. The alignment gap between IT and business is significant (81% vs. 59%), highlighting structural issues in infrastructure and collaboration.
From Doctor to Trading Master: Uncovering David Hung's M&A Strategy
Nuvation Bio founder and CEO David Hung has repeatedly achieved success in biotech M&A through scientific rigor and financial discipline. This article analyzes his deal strategies from Medivation to Nuvation, covering asset selection, non-dilutive financing, and pipeline development.
Pharmaceutical executives undergo密集 adjustments, signaling strategic transformation
Recent frequent executive changes at pharmaceutical companies such as Novo Nordisk, Genentech, and Allogene reflect deeper trends of strategic adjustment and pipeline optimization in the industry.